Blood Products: A Significant Risk Factor for Long-Term Catheter-Related Bloodstream Infections in Cancer Patients

2001 ◽  
Vol 22 (03) ◽  
pp. 165-166 ◽  
Author(s):  
Hend A. Hanna ◽  
Issam Raad

Abstract Data obtained from a previous prospective randomized study in cancer patients conducted at our institution were analyzed to investigate risk factors for catheter-related (CR) bloodstream infections (BSIs). Our recent analysis showed that the administration of blood products through central venous catheters was a risk factor for CR BSI, whereas thrombocytopenia during catheterization may have provided protection against CR BSI, as did central venous catheter insertion under maximal sterile barrier precautions.

2019 ◽  
Vol 6 (10) ◽  
Author(s):  
Johny Fares ◽  
Melissa Khalil ◽  
Anne-Marie Chaftari ◽  
Ray Hachem ◽  
Ying Jiang ◽  
...  

Abstract Objective Gram-negative organisms have become a major etiology of bloodstream infections. We evaluated the effect of central venous catheter management on cancer patients with gram-negative bloodstream infections. Method We retrospectively identified patients older than 14 years with central venous catheters who were diagnosed with gram-negative bloodstream infections to determine the effect of catheter management on outcome. Patients were divided into 3 groups: Group 1 included patients with central line-associated bloodstream infections (CLABSI) without mucosal barrier injury and those whose infection met the criteria for catheter-related bloodstream infection; group 2 included patients with CLABSI with mucosal barrier injury who did not meet the criteria for catheter-related bloodstream infection; and group 3 included patients with non-CLABSI. Results The study included 300 patients, with 100 patients in each group. Only in group 1 was central venous catheter removal within 2 days of bloodstream infection significantly associated with a higher rate of microbiologic resolution at 4 days compared to delayed central venous catheter removal (3–5 days) or retention (98% vs 82%, P = .006) and a lower overall mortality rate at 3-month follow-up (3% vs 19%, P = .01). Both associations persisted in multivariate analyses (P = .018 and P = .016, respectively). Conclusions Central venous catheter removal within 2 days of the onset of gram-negative bloodstream infections significantly improved the infectious outcome and overall mortality of adult cancer patients with catheter-related bloodstream infections and CLABSI without mucosal barrier injury.


2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 6101-6101
Author(s):  
Allison Nicole Lipitz Snyderman ◽  
Kent Sepkowitz ◽  
Elena B. Elkin ◽  
Laura C Pinheiro ◽  
Crystal Son ◽  
...  

6101 Background: This study’s objective was to examine administrative claims data’s capacity to serve as a surveillance tool for long-term catheter use and related bloodstream infections among cancer patients. Population-based estimates and efforts to track catheter use and infections for this group are limited. As such, we sought to explore catheter use documentation using a cohort of colorectal cancer patients. Methods: We performed a retrospective analysis using the population-based SEER-Medicare dataset for patients 66 years or older diagnosed with colorectal cancer in 2005-2007 (n = 54,870). Insertions and removals of long-term central venous catheters (i.e., tunneled, ports/pumps, peripherally inserted central catheter [PICCs]) were identified by billing codes within 2 years of diagnosis. Factors associated with catheter use were identified in multivariable logistic regression analysis. Results: Findings were consistent with clinical expectations. A total of 11,775 patients (21%) had at least one documented long-term catheter insertion within 2 years of diagnosis, 19% within 6 months. Of those with catheters, approximately 25% had more than one insertion. Sixty-eight percent had at least one port/pump, 8% at least one tunneled catheter, and 33% at least one PICC. Seventy-four percent of catheterized patients had IV chemotherapy. Of patients stages I, II, III, and IV, 10%, 18%, 37%, and 39% had catheters, respectively. Adjusted for other factors, patients with catheters were significantly more likely to be younger, female, black (vs. white), and have comorbidities (vs. none documented in year prior to diagnosis), compared to patients without catheters. By the end of the study, 34% of patients with ports/pumps had documented removal and 42% died (for patients with tunneled catheters, 28% and 52%, respectively). Conclusions: Findings support the use of claims data to capture long-term catheter use in cancer patients, providing a foundation for exploration of its capacity to capture infections. Given extensive documented catheter use (21%), infections may be a significant problem. Claims data may offer a low-burden method for surveillance and study, aiding the development of targeted initiatives.


Blood ◽  
2021 ◽  
Author(s):  
Helen Havens Clark ◽  
Lance Ballester ◽  
Hilary B Whitworth ◽  
Leslie Raffini ◽  
Char Witmer

Central venous catheters (CVC) are the most significant risk factor for pediatric venous thromboembolism (VTE). After an index CVC-associated VTE (CVC-VTE), the role of secondary prophylaxis for subsequent CVC placement is uncertain. Aims of this single center retrospective study were to evaluate the efficacy of secondary prophylaxis for patients with a prior CVC-VTE and identify risk factors associated with recurrent VTE in patients less than 19 years with an index CVC-VTE between 2003 and 2013. Data collection included clinical and demographic factors, subsequent CVC placement, secondary prophylaxis strategy, recurrent VTE, and bleeding. Risk factors for recurrence and effectiveness of secondary prophylaxis were evaluated using survival and binomial models. Among 373 patients with an index CVC-VTE, 239 (64.1%) had subsequent CVC placement. 17.4% (65/373) of patients had recurrent VTE, 90.8% (59/65) were CVC-associated. On multivariable survival analysis, each additional CVC (HR 12.00; 95% CI 2.78 - 51.91), congenital heart disease (HR 3.70; 95% CI 1.97 - 6.95), and total parenteral nutrition dependence (HR 4.02; 95% CI 2.23 - 7.28) were associated with an increased hazard of recurrence. Full dose anticoagulation for secondary prophylaxis was associated with decreased odds of recurrent CVC-VTE (OR 0.35; 95% CI 0.19 - 0.65) but not prophylactic dosing (OR 0.61; 95% CI 0.28 - 1.30). Only 1.3% of CVCs experienced major bleeding with prophylactic or full dose anticoagulation. In summary, children with CVC-VTE are at increased risk for recurrent VTE. Secondary prophylaxis with full dose anticoagulation was associated with a 65% reduction in odds of thrombotic events.


2018 ◽  
Vol 39 (2) ◽  
pp. 222-225 ◽  
Author(s):  
Anne Marie Chaftari ◽  
Ray Hachem ◽  
Sammy Raad ◽  
Ying Jiang ◽  
Elizabeth Natividad ◽  
...  

We evaluated the rate of central venous catheter (CVC) removal in 283 cancer patients with bloodstream infections (BSIs). Removal of CVCs occurred unnecessarily in 57% of patients with non-central-line-associated BSI (non-CLABSI), which was equivalent to the rate of CVC removal in patients with CLABSIs. Physician education and safe interventions to salvage the vascular access are warranted.Infect Control Hosp Epidemiol 2018;39:222–225


Blood ◽  
2008 ◽  
Vol 112 (7) ◽  
pp. 2703-2708 ◽  
Author(s):  
Cihan Ay ◽  
Ralph Simanek ◽  
Rainer Vormittag ◽  
Daniela Dunkler ◽  
Guelay Alguel ◽  
...  

Abstract Cancer patients are at high risk for venous thromboembolism (VTE). Laboratory parameters with a predictive value for VTE could help stratify patients into high- or low-risk groups. The cell adhesion molecule P-selectin was recently identified as risk factor for VTE. To investigate soluble P-selectin (sP-selectin) in cancer patients as risk predictor for VTE, we performed a prospective cohort study of 687 cancer patients and followed them for a median (IQR) of 415 (221-722) days. Main tumor entities were malignancies of the breast (n = 125), lung (n = 86), gastrointestinal tract (n = 130), pancreas (n = 42), kidney (n = 19), prostate (n = 72), and brain (n = 80); 91 had hematologic malignancies; 42 had other tumors. VTE occurred in 44 (6.4%) patients. In multivariable analysis, elevated sP-selectin (cutoff level, 53.1 ng/mL, 75th percentile of study population) was a statistically significant risk factor for VTE after adjustment for age, sex, surgery, chemotherapy, and radiotherapy (hazard ratio = 2.6, 95% confidence interval, 1.4-4.9, P = .003). The cumulative probability of VTE after 6 months was 11.9% in patients with sP-selectin above and 3.7% in those below the 75th percentile (P = .002). High sP-selectin plasma levels independently predict VTE in cancer patients. Measurement of sP-selectin at diagnosis of cancer could help identify patients at increased risk for VTE.


Medicine ◽  
2020 ◽  
Vol 99 (6) ◽  
pp. e19056 ◽  
Author(s):  
Jae Hwan Lee ◽  
Min Uk Kim ◽  
Eung Tae Kim ◽  
Dong Jae Shim ◽  
Il Jung Kim ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document